Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11003249 | 0.79 | MAPK1 (0.43) | KIF11MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL10451237 | 0.72 | MAPK1 (0.43) | KIF11MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL6599258 | 0.71 | KIF11 (0.45) | KIF11 | |
| SCHEMBL423133 | 0.70 | KIF11 (0.47) | KIF11TDP1 | |
| SCHEMBL3612411 | 0.70 | KIF11 (0.50) | KIF11MAPK1TDP1 | |
| SCHEMBL1722673 | 0.70 | KIF11 (0.47) | KIF11 | |
| SCHEMBL19563466 | 0.67 | KIF11 (0.53) | KIF11 | |
| SCHEMBL1721979 | 0.67 | KIF11 (0.44) | KIF11 | |
| SCHEMBL18768657 | 0.67 | KIF11 (0.44) | KIF11 | |
| SCHEMBL2560230 | 0.67 | KIF11 (0.44) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599467-B1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| EP-1599467-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1509509-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040116483-A1 | Glucagon antagonists/inverse agonists | BEHRENS CARSTEN (DK) | 2004-06-17 | — | — | US | disclosed |
| WO-2003097619-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2003-11-27 | — | — | WO | disclosed |
| US-6649641-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2002-12-12 | — | — | US | disclosed |
| US-4465682-A | Combating pests with substituted 3,6-diphenyl-3,4-dihydro-2H-1,3,5-oxadiazine-2,4-diones | BAYER AKTIENGESELLSCHAFT (DE) | 1984-08-14 | — | — | US | disclosed |
| US-4348394-A | Combating pests with substituted 3,6-diphenyl-3,4-dihydro-2H-1,3,5-oxadiazine-2,4-diones | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-07 | — | — | US | disclosed |
| EP-0014881-B1 | OXADIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PESTICIDES | BAYER AG (DE) | 1982-02-17 | — | — | EP | disclosed |
| EP-0007541-B1 | SUBSTITUTED 5-PHENYLCARBAMOYL-BARBITURIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS INSECTICIDES | BAYER AG (DE) | 1981-09-09 | — | — | EP | disclosed |
| US-4239762-A | INSECTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-16 | — | — | US | disclosed |
| EP-0007541-A1 | Substituted 5-phenylcarbamoyl-barbituric acids, process for their preparation and their use as insecticides | BAYER AG (DE) | 1980-02-06 | — | — | EP | disclosed |
| US-4103022-A | Combating arthropods with 3-(2,2,4,4-tetrafluoro-benz-1,3-dioxin-6-yl)-1-(substituted benzoyl)-ureas | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | KIF11 4465/4885MAPK1 679/4885TDP1 3618/4885 |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | KIF11 4465/4885MAPK1 679/4885TDP1 3618/4885 |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | KIF11 2711/4885MAPK1 856/4885TDP1 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.